4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
News 2026-09-15 13:31 UTC
SHELTON, CT / / September 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo E…
News 2026-09-15 13:25 UTC
NNVC - Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides
News 2026-09-08 12:30 UTC
NanoViricides (NNVC) said its Phase II clinical trial of NV-387 oral gummies to treat the current Bundibugyo Ebola outbreak has been registered in the Pan African Clinical Trials Database and is ready to go.
News 2026-07-06 12:40 UTC
NanoViricides, Inc. (NYSE: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it has continued to advance its broad-spectrum antiviral drug NV-387 towards a Phase II Clinical Trial of the NV-387 Oral Gummies formulation as a Treatment for the Current Bund